定量检测710例肝病患者HBsAg和HBeAg临床意义  

The clinical analysis of hepatitis B surface antigen and e antigen quantitative of 710 cases

作　　者：顾生旺[1] 张金荣[1] 赵兵[1] 李素娟[1] 杨文娟[1] 朱谦[1] 刘欢[1] 蒋兆荣[1] 吴德平[1] 

机构地区：[1]江苏省淮安市解放军第八二医院感染内科,223001

出　　处：《肝脏》2014年第6期420-422,共3页Chinese Hepatology

摘　　要：目的：了解乙型肝炎与肝硬化患者表面抗原（HBsAg）与e抗原（HBeAg）定量变化规律，探讨分层次联合抗病毒治疗并争取满意效果的可行性。方法采用荧光磁微粒酶免法检测710例 HBV 相关肝病患者 HBsAg 和HBeAg，用SPSS19．0软件包进行统计学处理。结果 HBsAg＜0．2 IU/mL 61例，占8．5％；HBsAg＞0．2 IU/mL～＜100 IU/mL 为低水平 HBsAg组，55例，占7．7％；HBsAg ＞100 IU/mL～＜1000 IU/mL 为中等水平 HBsAg 组，142例，占20％；HBsAg 1000～5000 IU/mL为高水平 HBsAg 组，211例，占29．7％；HBsAg＞5000 IU/mL 为超高水平HBsAg组，241例，占33．9％；各型肝炎随年龄增大，HBsAg 定量值逐步下降，转阴高峰集中在46岁左右；HBeAg 阴性组（＜1．0 CI）453例，占63．8％；低水平 HBeAg阳性组（＞1．0 CI～＜10 CI）96例，占13．5％；中等量水平 HBeAg 阳性组（＞10 CI～＜100 CI）55例，占7．7％；高水平 HBeAg 阳性组（＞100 CI～＜500 CI）23例，占3．2％；超高水平HBeAg阳性组（＞500 CI）83例，占11．6％；从慢性 HBV携带者，慢性乙型肝炎，代偿期肝硬化到失代偿期肝硬化，年龄逐步增大，HBsAg和 HBeAg定量秩均值逐步下降，卡方检验有显著性差异。结论 HBsAg 和 HBeAg 定量随年龄增加与病情发展逐步下降，根据 HBsAg，HBeAg 和 HBV DNA定量进行分层次联合抗病毒治疗可争取较满意效果。Objective To explore the relationship between HBsAg and HBeAg quantitation in patients with Hepatitis B and cirrhosis, and to investigate the feasibility of different levels anti-viral treatment and striving for satisfactory effect. Methods HBsAg and HBeAg concentrations were tested by fluorescent magnetic particle enzyme method in 710 patients with hepatitis B and cirrhosis, and data were statistically processed with SPSS （version 19. 0） software. Results A total of 61 patients （8.5%） had HBsAg 〈 0.2 IU/mL; 55 cases （7.7%） who had HBsAg〉 〉0.2 IU/mL-〈100 IU/mL were in low level of HBsAg group; 142 cases （20%） who had HBsAg〉100 IU/mL-〈1 000 IU/mL were in mid-level of HBsAg group; 211 cases （29.7%） who had HBsAg 1 000-5 000 IU/mL were in high level of HBsAg group; 241 cases （33.9%） who had HBsAg 〉 5000 IU/mL were in ultrahigh level of HBsAg group. HBsAg quantitative value gradually declined with age increasing in various types of hepatitis patients, and the peak age of HBsAg loss was focus on 46 years old. There were 453 patients （63. 8%） with HBeAg negative （〈1. 0 CI）. Low level of HBeAg positive group （〉1.0 CI-〈10 CI）, there were 96 cases （13.5%） ; mid level of HBeAg positive group （〉10 CI -〈100 CI）, there were 55 cases （7.7%）; high level of HBeAg positive group （〉100 CI-〈500 CI）, there were 23 cases （3.2%） ; ultrahigh level of HBeAg positive group （〉500 CI）, there were 83 cases （11.6%）. Among the patients of chronic HBV carriers, chronic hepatitis B, compensatory and decompensated cirrhosis, with the age increasing, their HBsAg and HBeAg quantitative mean ranks declined gradually, which showed a clear difference in chi-square inspection. Conclusions HBsAg and HBeAg quantitative ranks decline gradually by age increasing and illness developing. According to HBsAg, HBeAg and HBV DNA quantitation, hierarchical anti-viral treatment can strive for more ideal and satisfied effect.

关 键 词：肝炎 肝硬化 肝癌 乙型肝炎表面抗原 乙型肝炎E抗原 定量 

分 类 号：R512.62[医药卫生—内科学]